<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="367344">
  <stage>Registered</stage>
  <submitdate>7/11/2014</submitdate>
  <approvaldate>15/01/2015</approvaldate>
  <actrnumber>ACTRN12615000019505</actrnumber>
  <trial_identification>
    <studytitle>Effect of High Loading Dose of Atorvastatin in ST Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention on Microvascular Perfusion Measured by Index of Microvascular Resistance </studytitle>
    <scientifictitle>Effect of High Loading Dose of Atorvastatin in ST Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention on Microvascular Perfusion Measured by Index of Microvascular Resistance </scientifictitle>
    <utrn>U1111-1163-5214</utrn>
    <trialacronym />
    <secondaryid>'None'</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>ST Elevation Myocardial Infarction</healthcondition>
    <healthcondition>Myocardial Obstruction after Primary PCI</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>High loading dose of atorvastatin (80 mg) before primary PCI. Atorvastatin was given in oral tablet formulation immediately after patients was diagnosed as STEMI in emergency department and planned to do primary PCI</interventions>
    <comparator>Placebo that contain saccharum lactis powder packed in capsule. </comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Myocardial perfusion measured by index of microcirculatory resistance. Index of microcirculatory resistance measured using a pressure-temperature sensor-tipped wire. It needs maximal hyperemic state that induced by adenosine infusion 140 ug/kg/minutes</outcome>
      <timepoint>Immediateley after primary PCI was done (balloning and stenting of the culprit lesion)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>'None'</outcome>
      <timepoint>'None'</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>ST elevation minimal 0.1 mV in 2 concomittant ECG lead or new or presumably new LBBB 
</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Cardiogenic shock, respiratory distress, arrythmia, pregnancy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>numbered container</concealment>
    <sequence>simple randomization by randomization table</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>'none'</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>sample size was calculated by formula:  mean of 2 independent groups. We used alpha 95%, Zalpha 1.96 and beta 80%, Zbeta 0.84. S1=9, S2=25.2, (X1-X2) = 11.8. After calculation based on formula and above data, minimal sample are 32 samples in each group
statistical analysis: continuous data and categorical data. Bivariate analysis was done by student t test or Mann Whitney for continuous data. Categorical data was analysed by Chi square test or Fischer test</statisticalmethods>
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/01/2014</anticipatedstartdate>
    <actualstartdate>15/01/2014</actualstartdate>
    <anticipatedenddate>31/12/2014</anticipatedenddate>
    <actualenddate>15/12/2014</actualenddate>
    <samplesize>64</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Indonesia</country>
      <state>Jakarta</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Suci Indriani</primarysponsorname>
    <primarysponsoraddress>Departement Cardiology and Vascular Medicine, Faculty of Medicine University of Indonesia. Jl. S. Parman Kav 87, Slipi. Jakarta. Postcode 11420</primarysponsoraddress>
    <primarysponsorcountry>Indonesia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Suci Indriani</fundingname>
      <fundingaddress>Flamboyan 39, Kota Bambu Utara, Palmerah, Jakarta </fundingaddress>
      <fundingcountry>Indonesia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>dr. Doni Firman, SpJP</sponsorname>
      <sponsoraddress>Departement Cardiology and Vascular Medicine, Faculty of Medicine University of Indonesia. Jl. S. Parman Kav 87, Slipi. Jakarta. Postcode 11420</sponsoraddress>
      <sponsorcountry>Indonesia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>dr. Anwar Santoso, SpJP</sponsorname>
      <sponsoraddress>Departement Cardiology and Vascular Medicine, Faculty of Medicine University of Indonesia. Jl. S. Parman Kav 87, Slipi. Jakarta. Postcode 11420</sponsoraddress>
      <sponsorcountry>Indonesia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Background: Statin (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors), given before percutaneous coronary intervention (PCI) was proven to reduce Major Cardiovascular Events (MCE) in patient with stable angina as well as acute coronary syndromes through its pleiotropic effect. Nevertheless, the debate regarding statin administration before primary PCI (PPCI) in STEMI patients is still on the rise. The aim of this study is to establish therapeutic effect of high dose atorvastatin (80 mg) and placebo before primary PCI on microvascular perfusion in STEMI patient using index of microcirculatory resistance (IMR). IMR are specific and quantitative assessment of coronary microvascular dysfunction, reliable on-site predictors of short-term myocardial viability and left ventricle functional recovery of patients undergoing primary PCI for STEMI
Methods:  This study is a double blind randomized controlled trial. A high loading dose of atorvastatin (80 mg) or placebo was administered before PPCI. Samples were taken from the population of STEMI patients which underwent PPCI and meet inclusion and exclusion criteria. The primary end point of this study is IMR. After successful primary percutaneous coronary intervention, IMR was measured using a pressure-temperature sensor-tipped coronary guidewire.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>National Cardiovascular Center, Harapan Kita, Jakarta</ethicname>
      <ethicaddress>jl. S. Parman Kav 87, Jakarta. PO.BOX 11420</ethicaddress>
      <ethicapprovaldate>13/12/2013</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>1/12/2013</ethicsubmitdate>
      <ethiccountry>Indonesia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Suci Indriani</name>
      <address>Departement Cardiology and Vascular Medicine, Faculty of Medicine University of Indonesia. Jl. S. Parman Kav 87, Slipi. Jakarta. Postcode 11420</address>
      <phone>+62-85214739364</phone>
      <fax />
      <email>suci_fkui02@yahoo.com</email>
      <country>Indonesia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Suci Indriani</name>
      <address>Departement Cardiology and Vascular Medicine, Faculty of Medicine University of Indonesia. Jl. S. Parman Kav 87, Slipi. Jakarta. Postcode 11420</address>
      <phone>+62-85214739364</phone>
      <fax />
      <email>oechie.chan18@gmail.com</email>
      <country>Indonesia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Doni Firman, MD</name>
      <address>Departement Cardiology and Vascular Medicine, Faculty of Medicine University of Indonesia. Jl. S. Parman Kav 87, Slipi. Jakarta. Postcode 11420</address>
      <phone>+6281510369939</phone>
      <fax />
      <email>httpdoni_f@yahoo.com</email>
      <country>Indonesia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mrs</title>
      <name>Suci Indriani</name>
      <address>Jl. Flamboyan no. 39, Kota Bambu Utara, Jakarta Barat</address>
      <phone>+6285214739364</phone>
      <fax />
      <email>suci_fkui02@yahoo.com</email>
      <country>Indonesia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>